Paragon Care Limited · ASX:PGC
Paragon Care — Investor Presentation (February 2025)
13 slides from Paragon Care's investor presentation, Feb 27, 2025
Slide 1: Half Year Results Investor Presentation FY25
Half Year Results Investor Presentation FY25 27 February 2025 Paragon Care Limited ASX : PGC
Slide 2: Disclaimer
Disclaimer Summary information This Presentation contains summary information about ParagonCare, and its activities current as at 26/02/25. The information in the Presentation is of a general nature and does not purport to be complete or comprise all information which a shareholder or potential inve
Slide 3: Acknowledgement of Country
Acknowledgement of Country In the spirit of reconciliation ParagonCare acknowledges the Traditional Custodians of Country throughout Australia and their connections to land, sea and community. We pay our respect to their Elders past and present and extend that respect to all Aboriginal and Torres St
Slide 4: David Collins, Chief Executive Officer
David Collins Chief Executive Officer 4
Slide 5: Review of the half year
Review of the half year Revenue 28% $1.85 BILLION Half year 2025 EBITDA 103% $47.5 MILLION Net Profit After Tax 85.9% $13.2 MILLION Revenue $1.44 BILLION Half year 2024 EBITDA $23.4 MILLION $7.1 MILLION Net Profit After Tax * ParagonCare completed the merger with CH2 Holdings Pty Ltd on 3 June 2024.
Slide 6: FY24 P&L
FY24 P&L Underlying Result - $m HY25* HY24** Var $ Var % Commentary Revenue 1,850.4 1,636.6 213.8 13.1 Revenue on a like for like basis was solid: EBITDA 47.5 43.0 4.5 10.5 • Pharmacy continues to grow above market (as measured by IQVIA) • Capital & Service continues to be soft due to NZ government
Slide 7: FY24 Balance Sheet: Statutory
FY24 Balance Sheet: Statutory Commentary $m HY25 FY24 Var $ Var % Net working capital was up on June 24 due to this being the Receivables 403.0 346.3 56.7 16.4 peak working capital period for the CH2 business. Receivables Inventory 305.8 270.2 35.6 13.2 were up due to the revenue growth, and a numbe
Slide 8: Australia and New Zealand Overview
Australia and New Zealand Overview Revenue growth in line with expectations: $m HY25 HY24* Var $ Var % • Retail Pharmacy continues to grow with gains in market share. Pharmacy 1,420.3 1,222.3 198.0 16.2 • Hospital Pharmacy had modest growth due to being affected by price Medical Consumables 221.4 21
Slide 9: Asia Overview
Asia Overview Strong Revenue growth due to: $m HY25 HY24 Var $ Var % Aesthetics 30.9 17.1 13.8 80.7 • Aesthetics business grew strongly due to new products and strong Capital & Service 21.3 20.8 0.5 2.4 promotional activity • Imaging business was solid which offset lower service revenue – Asia Total
Slide 10: Executing on the integration plan
Executing on the integration plan On track for annual synergies of $5m in FY25 and $12m in FY26 New Organisational Eyecare business now on JDE • Oborne fully integrated onto ParagonCare Macquarie Engagement with all structure in place: ERP with eCommerce platform JDE ERP Park, Rosebery and Frenchs k
Slide 11: Strategic Overview
Strategic Overview Our Vision Diversified healthcare distributor Pharmaceuticals, capital Being the leading independent wholesaler & equipment (including Execute daily tasks distributor in the Asia Pacific healthcare market by ParagonCare service capability), Superior technology in a lean & efficien
Slide 12: FY25 Outlook
FY25 Outlook Continued execution on the integration plan for the merged entity. Increase cross-sell of expanded product range and bundled offerings. Focus on operational efficiency and cost rationalisation. Strategic focus on “One Team” way of doing business. Actively reviewing customer, product and
Slide 13: Thank you
Thank you